Safety, tolerability, pharmacokinetics and pharmacodynamics of a novel farnesoid X receptor (FXR) agonist-TQA3526 in healthy Chinese volunteers: a double-blind, randomized, placebo-controlled, dose-escalation, food effect phase I study

AbstractBackground: TQA3526 is a novel farnesoid X receptor agonist developed to treat non-alcoholic steatohepatitis (NASH) or primary biliary cholangitis (PBC). This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of TQA3526 in healthy Chinese pati...

وصف كامل

التفاصيل البيبلوغرافية

المؤلفون الرئيسيون:	Jia Xu, Hong Zhang, Hong Chen, Xiaoxue Zhu, Haiyan Jia, Zhongnan Xu, Dandan Huo, Cuiyun Li, Yanhua Ding
التنسيق:	Artigo
اللغة:	Inglês
منشور في:	Taylor & Francis Group 2023-12-01
سلاسل:	Annals of Medicine
الموضوعات:	TQA3526 pharmacokinetics pharmacodynamics safety tolerability food effect
الوصول للمادة أونلاين:	https://www.tandfonline.com/doi/10.1080/07853890.2023.2264850
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!